US EditionPublished • loading... • Updated
Pfizer and Metsera Enter Into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
Metsera's Board cites higher regulatory and legal risks in Novo Nordisk's bid and recommends Pfizer's offer of up to $86.25 per share for shareholder value and deal certainty.
- On Nov. 7, 2025, Metsera announced an amended merger agreement with Pfizer to acquire it for up to $86.25 per share, and the Metsera Board of Directors unanimously recommends stockholders approve it.
- In light of a U.S. Federal Trade Commission call, the Metsera Board of Directors said Novo Nordisk's two-step acquisition structure posed unacceptably high legal and regulatory risks, including potential challenges to the initial dividend.
- Novo Nordisk raised its offer on Thursday after Pfizer matched the prior $10 billion bid, fueling at least 16 separate offers and boosting Metsera shares over 14% yesterday and 55% since last week.
- The Metsera Board of Directors said the revised Pfizer terms offer the best value and certainty, creating real, immediate value and advancing Metsera's drug candidates.
- Analysts project the obesity market will hit $150 billion early next decade, while MET-097i and MET-233i could reach $5 billion in peak sales; Peter Kolchinsky said, 'Some assets are truly worth fighting over.
Insights by Ground AI
Podcasts & Opinions
82 Articles
82 Articles
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance - Metsera (NASDAQ:MTSR), Eli Lilly (NYSE:LLY)
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
·New York, United States
Read Full Article
The board of directors of the pharmaceutical company Metsera appears to have chosen a bid from Pfizer. It was otherwise expected that the buyer would be Novo Nordisk.
·Copenhagen, Denmark
Read Full Article
Danish pharmaceutical giant Novo Nordisk is losing the bidding war against competitor Pfizer to take over the pharmaceutical company Metsera, according to a press release.
·Stockholm, Sweden
Read Full Article
Coverage Details
Total News Sources82
Leaning Left12Leaning Right6Center25Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 28%
C 58%
14%
Factuality
To view factuality data please Upgrade to Premium
